跳转至内容
Merck

Y0001519

吡格列酮

European Pharmacopoeia (EP) Reference Standard

别名:

吡格列酮 盐酸盐, 5-[[4-[2-(5-一乙基-2-吡啶)乙氧基]苯基]甲基]-2,4-噻唑烷二酮 单盐酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H20N2O3S · HCl
分子量:
392.90
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

pioglitazone

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

Cl.CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1

InChI

1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H

InChI 密鑰

GHUUBYQTCDQWRA-UHFFFAOYSA-N

基因資訊

human ... PPARG(5468)

正在寻找类似产品? 访问 产品对比指南

一般說明

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

應用

用于系统适用性的匹格列酮EP参考标准品的预期用途是欧洲药典规定的实验室测试。

生化/生理作用

盐酸吡格列酮是一种PPARγ激动剂和噻唑烷二酮(TZD)抗糖尿病药物。吡格列酮是一种核受体过氧化物酶体增殖物激活受体γ(PPAR-γ)的选择性激动剂,并在较小程度上是PPAR-α

包裝

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他說明

可能适用相应的销售限制。

象形圖

Health hazardExclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Carc. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Chin-Hsiao Tseng
Metabolism: clinical and experimental, 63(8), 1049-1055 (2014-06-04)
To investigate whether pioglitazone treatment of patients with type 2 diabetes mellitus was associated with an increased risk of kidney cancer. The reimbursement databases of all Taiwanese patients with type 2 diabetes who received oral anti-diabetic agents or insulin from
The use of oral pioglitazone in the treatment of lichen planopilaris.
Natasha Atanaskova Mesinkovska et al.
Journal of the American Academy of Dermatology, 72(2), 355-356 (2015-01-17)
W Xu et al.
Journal of internal medicine, 277(1), 137-150 (2014-07-22)
Progressive β-cell dysfunction hinders the maintenance of glycaemic control in type 2 diabetes, but comparative data on β-cell-protective therapies are lacking in the early stage of type 2 diabetes. Here we evaluated the comparative glycaemic efficacy and impact on β-cell
M Suzuki et al.
Nutrition & diabetes, 4, e125-e125 (2014-07-08)
Tofogliflozin, a highly selective inhibitor of sodium/glucose cotransporter 2 (SGLT2), induces urinary glucose excretion (UGE), improves hyperglycemia and reduces body weight in patients with Type 2 diabetes (T2D). The mechanisms of tofogliflozin on body weight reduction were investigated in detail
Zhan Shi et al.
Pakistan journal of pharmaceutical sciences, 27(3), 537-539 (2014-05-09)
Raw Radix Rehmanniae (RRR) is a frequently used traditional Chinese medicine in the treatment of diabetes mellitus according to the statistics on all of the anti-diabetic formulas recorded in New National Traditional Chinese Medicine. Pioglitazone and RRR may be co-administrated

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门